In a phase 3 trial, inebilizumab, a monoclonal antibody targeting CD19+ B cells, reduced flare rates and improved treatment-free and glucocorticoid-free remission in patients with immunoglobulin G4-related...
A recent study found that carrimycin significantly improved immune function and reduced disease severity in patients with tumors who have sepsis, highlighting its potential as an effective immune-modulating...
